Search results for " administration"

showing 10 items of 4299 documents

Superiority of the Triple Combination of Bortezomib-Thalidomide-Dexamethasone Over the Dual Combination of Thalidomide-Dexamethasone in Patients With…

2012

Purpose This prospective multicenter phase III study compared the efficacy and safety of a triple combination (bortezomib-thalidomide-dexamethasone [VTD]) versus a dual combination (thalidomide-dexamethasone [TD]) in patients with multiple myeloma (MM) progressing or relapsing after autologous stem-cell transplantation (ASCT). Patients and Methods Overall, 269 patients were randomly assigned to receive bortezomib (1.3 mg/m2 intravenous bolus) or no bortezomib for 1 year, in combination with thalidomide (200 mg per day orally) and dexamethasone (40 mg orally once a day on 4 days once every 3 weeks). Bortezomib was administered on days 1, 4, 8, and 11 with a 10-day rest period (day 12 to day …

AdultMaleCancer Researchmedicine.medical_specialtyTransplantation AutologousGastroenterologyDexamethasoneDisease-Free SurvivalDrug Administration ScheduleSettore MED/01 - Statistica MedicaBortezomib03 medical and health sciences0302 clinical medicineRecurrenceInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansAutologous transplantationSurvival rateMultiple myelomaDexamethasoneAgedBortezomibbusiness.industryHazard ratioTranslational research Immune Regulation [ONCOL 3]Middle Agedmedicine.diseaseBoronic AcidsThalidomide3. Good healthSurgeryThalidomideTransplantationTreatment OutcomeOncologyPyrazines030220 oncology & carcinogenesisFemaleMultiple MyelomabusinessStem Cell Transplantation030215 immunologymedicine.drugJournal of Clinical Oncology
researchProduct

Weekly Levofolinic Acid and 5-Fluorouracil Plus Hydroxyurea in Metastatic Gastrointestinal Adenocarcinomas

1994

There were 42 patients with advanced gastrointestinal carcinomas (GA) enrolled in the study. In the Phase I part of the study we identified the MTD of 5-fluorouracil (5FU) in combination with levofolinic acid 100 mg/m2 per week intravenously plus hydroxyurea 1 g/m2 per week given by mouth in 3 refracted doses starting 6 hours after 5FU was administered. This treatment was given weekly for 6 consecutive weeks followed by a 15-day rest period. We were not able to increase 5FU weekly dosage above 700 mg/m2 due to the occurrence of grade 3-4 gastrointestinal toxicity. Thus 5FU was employed at 600 mg/m2 per week for the Phase II part of the study. Among 20 evaluable patients with measurable meta…

AdultMaleCancer Researchmedicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentLeucovorinRectumAdenocarcinomaGastroenterologyAntimetaboliteDrug Administration ScheduleHydroxycarbamideInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansHydroxyureaAgedGastrointestinal NeoplasmsChemotherapybusiness.industryMiddle AgedSurvival AnalysisSurgeryRegimenmedicine.anatomical_structureOncologyFluorouracilToxicityVomitingFemaleFluorouracilmedicine.symptombusinessmedicine.drugAmerican Journal of Clinical Oncology
researchProduct

Vinorelbine plus cisplatin in recurrent or previously untreated unresectable squamous cell carcinoma of the head and neck

1995

Despite considerable progress achieved in the management of head and neck carcinomas (HNC) in the last decade, the prognosis of patients with advanced squamous cell HNC is still dismal. On the basis of the reported good activity of a new vinca alkaloid derivative, i.e., vinorelbine (VNR), we tested the combination of cisplatin and VNR in a series of patients with recurrent or previously untreated unresectable squamous cell HNC. Thirty-five patients with recurrent or previously untreated unresectable squamous cell HNC were treated with a combination of cisplatin 80 mg/m2 on day 1, plus vinorelbine 25 mg/m2 i.v. push on days 1 and 8. This cycle was repeated every 3 weeks. Analysis of response…

AdultMaleCancer Researchmedicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentVinblastineVinorelbineGastroenterologyDrug Administration ScheduleVinca alkaloidInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansAgedCisplatinChemotherapybusiness.industryRemission InductionVinorelbineMiddle AgedVinblastineSurgeryRadiation therapyRegimenOncologyHead and Neck NeoplasmsCarcinoma Squamous CellVomitingFemaleCisplatinNeoplasm Recurrence Localmedicine.symptombusinessmedicine.drug
researchProduct

Sublingual administration of captopril in patients with acute myocardial ischemia.

1991

Summary: To investigate the anti-ischemic capability of the angiotensin-converting enzyme inhibitor captopril, 10 patients with acute myocardial ischemia (angina pectoris >1 h, ST-segment depression ±0.1 mV, no rise in creatine phosphokinase) received 25 mg captopril sublingually after being treated with an intravenous infusion of nitroglycerin (3 mg/h) and heparin (1200 IU/h) for 1 hour. A control group of 10 patients received placebo instead of captopril. Results showed a decrease of the initial ST-segment depression from 0.25±0.04 to 0.2±0.03 mV (p>0.01) with nitroglycerin for the captopril group and from 0.26±0.05 to 0.21±0.05 mV (p>0.01) for the control group. An additional decrease to…

AdultMaleCaptoprilAdministration SublingualCoronary DiseasePlaceboSublingual administrationAngina PectorisAnginaElectrocardiographyNitroglycerinHeart ratemedicineHumanscardiovascular diseasesMyocardial infarctionCreatine KinaseClinical Trials as Topicbiologybusiness.industryHemodynamicsCaptoprilGeneral MedicineMiddle Agedmedicine.diseasemedicine.anatomical_structureAnesthesiaAcute DiseaseVascular resistancebiology.proteinCreatine kinaseDrug Therapy CombinationFemaleCardiology and Cardiovascular Medicinebusinessmedicine.drugClinical cardiology
researchProduct

Sublingual administration of captopril versus nitroglycerin in patients with severe congestive heart failure.

1990

Angiotensin-converting enzyme inhibition has proven to be a successful approach for the long-term treatment of patients with congestive heart failure. This investigation compared the acute hemodynamic changes after sublingual administration of the angiotensin-converting enzyme inhibitor captopril with those after nitroglycerin. A total of 24 patients with severe left heart failure (New York Heart Association classes III and IV) were given 25 mg captopril and 0.8 mg nitroglycerin sublingually in this randomized, cross-over study. Hemodynamic monitoring revealed a clear improvement in pre- and afterload parameters for both drugs (P less than 0.01 and P less than 0.001), while captopril induce…

AdultMaleCaptoprilCardiac indexAdministration SublingualHemodynamicsSublingual administrationNitroglycerinAfterloadmedicineHumanscardiovascular diseasesAgedHeart Failurebiologybusiness.industryHemodynamicsCaptoprilAngiotensin-converting enzymeStroke volumeMiddle Agedmedicine.diseaseAnesthesiaHeart failurebiology.proteinFemaleVascular ResistanceCardiology and Cardiovascular Medicinebusinesscirculatory and respiratory physiologymedicine.drugInternational journal of cardiology
researchProduct

Altered benzodiazepine receptor sensitivity in alcoholism: a study with fMRI and acute lorazepam challenge.

2007

Previous studies suggested altered sensitivity of the GABA/benzodiazepine receptor system in alcoholic patients. Expanding on these findings, the present functional magnetic resonance imaging (fMRI) study aimed to assess whether a differential modulation of cognitive brain activation by an acute GABAergic drug challenge could be detected in patients with alcoholism. Eight detoxified male patients meeting DSM-IV criteria for alcohol dependence and nine healthy male control subjects were studied with fMRI while performing a 2-back working memory task. The fMRI scans were performed 1 h after intravenous administration of saline and again 1 h after 0.03 mg/kg lorazepam I.V. After saline, a task…

AdultMaleCerebellummedicine.medical_specialtyPsychometricsmedicine.drug_classNeuroscience (miscellaneous)Prefrontal CortexLorazepamDrug Administration ScheduleInternal medicineCerebellummedicineHumansRadiology Nuclear Medicine and imagingGABA ModulatorsBenzodiazepineMemory Disordersmedicine.diagnostic_testWorking memoryAlcohol dependenceLorazepamReceptors GABA-AMagnetic Resonance ImagingFunctional imagingPsychiatry and Mental healthAlcoholismmedicine.anatomical_structureEndocrinologySedativePsychologyFunctional magnetic resonance imagingCognition DisordersNeuroscienceChlormethiazolemedicine.drugPsychiatry research
researchProduct

Early viral clearance and sustained response in chronic hepatitis C: a controlled trial of interferon and ribavirin after high-dose interferon induct…

2002

High-dose induction with alpha-interferon induces early viral clearance of hepatitis C and combined with ribavirin enhances sustained response. We assess whether adding ribavirin after viral clearance obtained by alpha-interferon induction increased the rate of viral eradication.Forty-one naïve patients with chronic hepatitis C were randomised to receive, after 4 weeks of 10 mU daily of alpha-interferon (induction), 3 mU daily for 22 weeks and 3 mU thrice weekly for 26 weeks of either interferon alone (monotherapy) or interferon plus 1000-1200 mg daily of ribavirin (combination therapy). At the end of the induction phase, 23 (56%) subjects had cleared HCV-RNA. During therapy, breakthrough w…

AdultMaleCombination therapyAdolescentHepacivirusAlpha interferonViremiaEnzyme-Linked Immunosorbent AssayHepacivirusPharmacologyAntiviral AgentsDrug Administration Schedulelaw.inventionchemistry.chemical_compoundRandomized controlled trialInterferonlawVirologyRibavirinHumansMedicineViremiaAgedAntiviral AgentHepatologybiologyDose-Response Relationship Drugbusiness.industryRibavirinvirus diseasesInterferon-alphaHepatitis CHepatitis C ChronicMiddle Agedbiology.organism_classificationmedicine.diseaseInfectious DiseasesTreatment OutcomechemistryRNA ViralDrug Therapy CombinationFemalebusinessmedicine.drugHuman
researchProduct

Temsirolimus for the treatment of mantle cell lymphoma.

2010

Although recent progress has been made in the treatment of mantle cell lymphoma (MCL) the majority of patients experience relapse and ultimately die of their disease. The translocation t(11;14) is a prerequisite for the diagnosis of MCL and results in overexpression of cyclin D1. Its protein translation is controlled by mTOR, a key element of the PI3K/Akt pathway, and mTOR constitutes an attractive therapeutic target. Temsirolimus, a specific inhibitor of mTOR, has been evaluated in two Phase II trials in patients with relapsed MCL, and promising response rates up to 40% were found. Subsequently, a randomized Phase III trial was initiated, in which superiority in remission induction and pro…

AdultMaleCombination therapyChromosomal translocationAntineoplastic AgentsLymphoma Mantle-CellPharmacologyDisease-Free SurvivalDrug Administration ScheduleCyclin D1hemic and lymphatic diseasesmedicineSecondary PreventionHumansCyclin D1PI3K/AKT/mTOR pathwayAgedAged 80 and overSirolimusClinical Trials as Topicbusiness.industryTOR Serine-Threonine KinasesRemission InductionIntracellular Signaling Peptides and ProteinsHematologyMiddle Agedmedicine.diseaseTemsirolimusNon-Hodgkin's lymphomaRegimenCancer researchMantle cell lymphomaFemalebusinessmedicine.drugExpert review of hematology
researchProduct

Understanding symptoms in RYR1-Related Myopathies: A mixed-methods analysis based on participants' experience

2020

Background: In rare diseases such as ryanodine receptor 1-related myopathies (RYR1-RM), health-related quality of life (HRQoL) measures are critically important so clinicians and researchers can better understand what symptoms are most important to participants, with the ultimate goal of finding tangible solutions for them. Objectives: The main objective of this study was to characterize symptoms in individuals with RYR1-RM to inform future research. A secondary objective of this study was to analyze positive and negative sentiments regarding symptoms and treatment effects post N-acetylcysteine (NAC) administration in individuals with RYR1-RM. Methods: The study used a mixed-methods design …

AdultMaleCoping (psychology)medicine.medical_specialtyWeaknessMEDLINEPainQualitative propertyArticleHealth administrationlaw.inventionInterviews as Topic03 medical and health sciences0302 clinical medicineDouble-Blind MethodMuscular DiseasesRandomized controlled triallawAdaptation PsychologicalHumansMedicine030212 general & internal medicineChildFatigueEsportsHealth economicsbusiness.industry030503 health policy & servicesPublic healthRyanodine Receptor Calcium Release ChannelMiddle AgedAcetylcysteineSocioeconomic FactorsQuality of LifeFemaleEducació físicamedicine.symptom0305 other medical sciencebusinessClinical psychology
researchProduct

Platelet aggregation, ATP release and cytoplasmic Ca2+ movement: the effects of cloricromene.

1994

A placebo-controlled, double-blind, randomized, cross-over study was performed in 24 healthy volunteers. 12 volunteers received Cloricromene (100mg gastroresistant capsules twice a day) for 7 days, the other volunteers received identical placebo capsules. Subsequently, after a 7-day wash-out period, at day 15, each subject received the other treatment. Blood samples were taken on days 1 and 15 (1st day of each treatment) as well as on days 7 and 21 (7th day of each treatment) before the morning drug administration and 2 and 4 hours later. Platelet aggregation and ATP secretion were studied in whole blood (WB) using ADP and collagen as stimulating agents. Ca2+ fluxes were studied in aequorin…

AdultMaleCytoplasmAdolescentPlatelet Aggregationchemistry.chemical_elementAdministration OralPharmacologyCalciumPlaceboAdenosine TriphosphateDouble-Blind MethodOral administrationHumansPlateletSecretionWhole bloodCalcium metabolismCross-Over StudiesChemistryChromonarHematologyMiddle AgedCrossover studyAdenosine DiphosphateAnesthesiaCalciumFemaleCollagenPlatelet Aggregation InhibitorsThrombosis research
researchProduct